By Chris Wack
IGM Biosciences has decided to halt development of imvotamab and IGM-2644, two IgM-based bispecific antibody T cell engagers for autoimmune diseases, and cut its staff by 73%.
The biotechnology company said interim data from Phase 1b studies showed insufficient B cell depletion for imvotamab in treating rheumatoid arthritis and lupus.
IGM-2644 is also being terminated following strategic considerations.
The company is now exploring internal options and strategic alternatives to maximize shareholder value, while implementing a 73% workforce reduction to conserve cash.
As of Dec. 31, IGM had $183.8 million in cash and investments.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 09, 2025 13:23 ET (18:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.